Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

891 questions · 902 findings · 317 reviews

No studies found 210 · 23.3%GRADE not reported 56 · 6.2%Very low 236 · 26.2%Low 220 · 24.4%Moderate 146 · 16.2%High 34 · 3.8%

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Specific adverse events: thromboembolic events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Sclerotherapy vs no intervention

Serious adverse events and liver‐related morbidity: incidence of bleeding from gastric varices · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis

It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).

1 finding from 1 review

Sclerotherapy vs no intervention

Serious adverse events and liver‐related morbidity: incidence of congestive hypertensive gastropathy · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis

It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).

1 finding from 1 review

Combination of manual therapy and exercise following joint distension vs sham ultrasound following joint distension

Adverse events · patients with adhesive capsulitis (frozen shoulder)

Combination of manual therapy and exercise following joint distension leads to lower adverse events compared with sham ultrasound following joint distension (high certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher adverse events: infections (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review